Patents by Inventor Mitchell S. Steiner

Mitchell S. Steiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYMORPHS OF [2-(1H-INDOL-3-YL)-1H-IMIDAZOL-4-YL](3,4,5-TRIMETHOXY)METHANONE AND ITS SALTS
    Publication number: 20230348433
    Abstract: The invention encompasses polymorphs of [2-(1H-indol-3-yl)-1H-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone and salts thereof. These polymorphs are characterized by their x-ray diffraction pattern and DSC thermograms, among other methods. The polymorphs are used in the preparation of pharmaceutical compositions and products.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 2, 2023
    Applicant: VERU INC.
    Inventors: Thomas Gary BIRD, Kester Gary BARNETTE, Mitchell S. STEINER
  • METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS
    Publication number: 20230321045
    Abstract: The present invention relates to methods of treating specific viral infections using compounds having anti-tubulin or tubulin disruption activity.
    Type: Application
    Filed: April 7, 2023
    Publication date: October 12, 2023
    Applicant: VERU INC.
    Inventors: Mitchell S. STEINER, Kester Gary BARNETTE
  • METHODS OF TREATING CORONAVIRUS
    Publication number: 20230265081
    Abstract: The present invention relates to methods of treating coronavirus infections using compounds having anti-tubulin or tubulin disruption activity.
    Type: Application
    Filed: April 11, 2023
    Publication date: August 24, 2023
    Applicant: VERU INC.
    Inventors: Mitchell S. Steiner, Kester Gary Barnette
  • METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTS
    Publication number: 20230172897
    Abstract: This invention relates to pharmaceutical compositions comprising a selective androgen receptor modulator (SARM) compound of Formulae I-XIV and an additional therapeutic agent and uses thereof for treating a breast cancer. The method of the treatment of the invention, in some embodiments, further comprises a step, prior to the treatment, of prescreening a breast cancer subject for whether the breast cancer is susceptible to selective androgen receptor modulator (SARM) treatment.
    Type: Application
    Filed: February 11, 2022
    Publication date: June 8, 2023
    Applicant: VERU, INC.
    Inventors: Mitchell S. STEINER, Kester Gary BARNETTE
  • Methods of treating coronavirus
    Patent number: 11648236
    Abstract: The present invention relates to methods of treating coronavirus infections using compounds having anti-tubulin or tubulin disruption activity.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: May 16, 2023
    Assignee: VERU INC.
    Inventors: Mitchell S. Steiner, Kester Gary Barnette
  • METHODS OF PRESCREENING AND TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
    Publication number: 20220257552
    Abstract: This invention relates to methods of prescreening and treatment of a breast cancer in a subject, and the subject can be either a male or female subject, including methods of prescreening then treating: metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed treatments with selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), fulvestrant, cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio), trilaciclib, lerociclib), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3K?)), mTOR inhibitor (everolimus), poly ADP ribose polymerase (PARP) inhibitor
    Type: Application
    Filed: February 11, 2022
    Publication date: August 18, 2022
    Applicant: Veru, Inc.
    Inventors: Mitchell S. Steiner, Kester Gary Barnette
  • METHODS OF TREATING CORONAVIRUS
    Publication number: 20210308105
    Abstract: The present invention relates to methods of treating coronavirus infections using compounds having anti-tubulin or tubulin disruption activity.
    Type: Application
    Filed: April 5, 2021
    Publication date: October 7, 2021
    Applicant: VERU INC.
    Inventors: Mitchell S. STEINER, Kester Gary BARNETTE
  • PHARMACEUTICAL COMPOSITIONS FOR TREATING BREAST CANCERS AND METHODS OF USES THEREOF
    Publication number: 20210228529
    Abstract: This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject.
    Type: Application
    Filed: January 15, 2021
    Publication date: July 29, 2021
    Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Mitchell S. STEINER, Ramesh NARAYANAN, Sunjoo AHN, James T. DALTON
  • NON-INVASIVE METHOD OF EVALUATING BREAST CANCERS FOR SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM) THERAPY
    Publication number: 20210128513
    Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject.
    Type: Application
    Filed: October 9, 2020
    Publication date: May 6, 2021
    Applicant: UN IVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Mitchell S. Steiner, Ramesh NARAYANAN, Sunjoo AHN, James T. DALTON
  • Non-invasive method of evaluating breast cancers for selective androgen receptor modulator (SARM) therapy
    Patent number: 10849873
    Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: December 1, 2020
    Assignee: ONCTERNAL THERAPEUTICS, INC
    Inventors: Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn, James T. Dalton
  • COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS
    Publication number: 20200282008
    Abstract: The invention provides compositions and methods for long term release of gonadotropin-releasing hormone (GnRH) antagonists and uses thereof. Specifically, the invention provides polymer compositions and methods for controlled release of GnRH antagonists.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 10, 2020
    Inventors: Ravi KACKER, Mitchell S. STEINER, Jui-Chen LIN, Andrew Michael CERRO, Christopher A. RHODES
  • COMPOUNDS FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND OVARIAN CANCER
    Publication number: 20190389841
    Abstract: The present invention encompasses methods of treating triple negative breast cancer and/or ovarian cancer using therapeutically effective amounts of compounds represented by the structure of formula I.
    Type: Application
    Filed: May 15, 2019
    Publication date: December 26, 2019
    Applicants: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, VERU INC
    Inventors: Wei LI, Duane D. MILLER, Shanshan DENG, Raya KRUTILINA, Tiffany N. SEAGROVES, Junming YUE, Guannan ZHAO, Wang QINGHUI, Mitchell S. STEINER
  • Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
    Patent number: 10314807
    Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and/or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: June 11, 2019
    Assignee: GTX, INC.
    Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn
  • NON-INVASIVE METHOD OF EVALUATING BREAST CANCERS FOR SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM) THERAPY
    Publication number: 20190125716
    Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 2, 2019
    Applicant: GTx, INC.
    Inventors: Mitchell S. STEINER, Ramesh Narayanan, Sunjoo Ahn, James T. Dalton
  • Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
    Patent number: 10258596
    Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and/or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: April 16, 2019
    Assignee: GTx, Inc.
    Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn
  • COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS
    Publication number: 20180250354
    Abstract: The invention provides compositions and methods for long term release of Gonadotropin-releasing hormone (GnRH) antagonists and uses thereof. Specifically, the invention provides polymer compositions and methods for controlled release of GnRH antagonists.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 6, 2018
    Inventors: RAVI KACKER, Mitchell S. Steiner
  • COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS
    Publication number: 20180214507
    Abstract: The invention provides compositions and methods for long term release of Gonadotropin-releasing hormone (GnRH) antagonists, and uses thereof. Specifically, the invention provides polymer compositions and methods for controlled release of GnRH antagonists.
    Type: Application
    Filed: January 31, 2018
    Publication date: August 2, 2018
    Inventors: Ravi Kacker, Mitchell S. Steiner
  • Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
    Patent number: 9969683
    Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject. The breast cancer includes metastatic breast cancer, refractory breast cancer, AR-positive breast cancer, AR-positive refractory breast cancer, AR-positive metastatic breast cancer, AR-positive and ER-positive breast cancer, triple negative breast cancer, advanced breast cancer, breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments, and metastasis in a subject suffering from breast cancer. The method comprises administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: May 15, 2018
    Assignee: GTX, INC.
    Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn
  • Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
    Patent number: 9744149
    Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: August 29, 2017
    Assignee: GTX, INC.
    Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn
  • METHOD OF TREATING HER2-POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS)
    Publication number: 20170209407
    Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and/or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
    Type: Application
    Filed: December 6, 2016
    Publication date: July 27, 2017
    Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn